Favourable Rulings, Upcoming Conferences, Clinical Study Results, Drug Availability, and Tender Offers - Research Reports on United Therapeutics, Illumina, AstraZeneca, Eli Lilly and Abbott

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, September 3, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding United Therapeutics Corporation (NASDAQ: UTHR), Illumina, Inc. (NASDAQ: ILMN), AstraZeneca plc (NYSE: AZN), Eli Lilly and Co. (NYSE: LLY) and Abbott Laboratories (NYSE: ABT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6174-100free.

--
United Therapeutics Corporation Research Reports
On August 29, 2014, United Therapeutics Corporation (United Therapeutics) announced that the U.S. District Court for the District of New Jersey has given its judgment in favor of the Company in relation to its case against Sandoz, Inc. (Sandoz) regarding its Remodulin® product. The Company informed that Judge Peter Sheridan ruled that U.S. Patent No. 6,765,117 is both valid and enforceable against Sandoz, Inc., and enjoined Sandoz from marketing its generic product until the patent expires in October 2017. Further, Judge Sheridan also ruled that U.S. Patent No. 7,999,007 which expires in 2029 is valid, but would not be infringed by Sandoz' generic product. The Company added that Sandoz filed an Abbreviated New Drug Application in December 2011 seeking to market a generic version of Remodulin, and challenged patents covering Remodulin under that application. The full research reports on United Therapeutics are available to download free of charge at:

http://www.analystsreview.com/Sep-03-2014/UTHR/report.pdf

--
Illumina, Inc. Research Reports
On August 27, 2014, Illumina, Inc. (Illumina) announced that the Company will provide a live webcast of its presentation to be held at the Morgan Stanley Global Healthcare Conference in New York on September 9, 2014. The Company stated that the webcast will begin at 2:55 p.m. EDT and will include a brief overview of the Company by its CEO, Jay Flatley, followed by a question and answer session. The webcast will be available on the Company's official website under the Investor Relations section. The full research reports on Illumina are available to download free of charge at:

http://www.analystsreview.com/Sep-03-2014/ILMN/report.pdf

--
AstraZeneca plc Research Reports
On September 1, 2014, AstraZeneca plc (AstraZeneca) announced the results of its Phase IV ATLANTIC study, which were also published in the New England Journal of Medicine. The data from the study indicates that the profile of BRILINTA/BRILIQUE™ (ticagrelor) is comparable whether administered in a pre-hospital or in-hospital setting to ST segment elevation myocardial infarction (STEMI) patients. The Company informed that the ATLANTIC was designed to evaluate pre-hospital administration versus in-hospital administration of ticagrelor in terms of pre-percutaneous coronary intervention (PCI) - or angioplasty - procedural effectiveness, bleeding at 24 hours and 30 days and the pre-specified composite endpoint of death, MI, stroke, urgent revascularisation and definite acute stent thrombosis at 30 days. AstraZeneca added that these results are in line with new ESC/EACTS 2014 Guidelines on Myocardial Revascularisation which give a class I recommendation to start dual antiplatelet therapy in STEMI patients at first medical contact. The full research reports on AstraZeneca are available to download free of charge at:

http://www.analystsreview.com/Sep-03-2014/AZN/report.pdf

--
Eli Lilly and Co. Research Reports
On August 26, 2014, Eli Lilly and Co. (Eli Lilly), along with Boehringer Ingelheim Pharmaceuticals, Inc., reported the availability of Jardiance® (empagliflozin) tablets by prescription in pharmacies across the U.S. such as Walgreens, Rite Aid, Kroger and others. Eli Lilly informed that JARDIANCE was approved by the U.S. Food and Drug Administration (FDA) on August 1, 2014 as an adjunct to diet and exercise to improve glycemic control, or blood glucose levels, in adults with type 2 diabetes (T2D). The FDA's approval was based on results from a large clinical program comprised of over 10 multinational clinical trials and more than 13,000 adults with T2D. In addition, the Company stated that JARDIANCE is not for people with type 1 diabetes or for people with diabetic ketoacidosis (increased ketones in the blood or urine). According to Eli Lilly, the JARDIANCE Simple Savings co-pay support program is available both online and in many doctors' offices. The full research reports on Eli Lilly are available to download free of charge at:

http://www.analystsreview.com/Sep-03-2014/LLY/report.pdf

--
Abbott Laboratories Research Reports
On August 25, 2014, Abbott Laboratories (Abbott) announced that the Company's wholly-owned subsidiary, Abbott Laboratories (Chile) Holdco (Dos) SpA, a Chilean corporation (ALH), has commenced a tender offer (the "U.S. Offer") to purchase: 1) from U.S. holders only, up to 100% of the outstanding ordinary, nominative, no par value shares of CFR Pharmaceuticals S.A. and 2) from all holders, wherever resident, up to 100% of the outstanding American Depositary Shares, each of which represents 100 Ordinary Shares. The U.S. offer is scheduled to expire on September 23, 2014 at 5 p.m. New York City time. ALH is also making an offer (the "Chilean Offer") to purchase up to 100% of the outstanding Ordinary Shares from all holders of Ordinary Shares, wherever resident, for the same price and on substantially the same terms as ALH is offering to purchase Ordinary Shares pursuant to the U.S. Offer (except that tendering holders in the Chilean Offer can elect to be paid in Chilean pesos). The full research reports on Abbott are available to download free of charge at:

http://www.analystsreview.com/Sep-03-2014/ABT/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Analysts Review

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.